Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sofiva Genomics Co (6615) Fair Value & Analysis

Healthcare · TW · Market cap 767M TWD

Price37.70 TWD
Fair Value8.94 TWD
Upside-76.3%
Quality95/100
Evidence: Medium Range 7.75 TWD – 10.12 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Sofiva Genomics Co (6615) currently trades at 37.70 TWD, while our model-based Fair Value estimate is 8.94 TWD — implying the stock looks roughly 76.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Sofiva Genomics Co.,Ltd. provides pre-pregnancy, prenatal, and newborn genetic testing and medical testing services in Taiwan and internationally. The company offers reproductive testing services, including preimplantation genetic testing for aneuploidy (PGT-A), non-invasive preimplantation genetic testing for aneuploidy (niPGT-A), and preimplantation genetic testing for monogenic diseases (PGT-M); and prenatal testing services, such as non-invasive prenatal screening, array, karyotyping, maternal serum screening for down syndrome, risk assessment for early/late-onset preeclampsia, folate metabolism genetic testing, congenital infection screening,carrier scan, thalassemia genetic testing, spinal muscular atrophy genetic testing, and fragile X syndrome genetic testing. It also provides baby genetic testing comprising sensorineural hearing loss genetic testing; congenital central hypoventilation syndrome genetic testing (CCHS); and congenital cytomegalovirus infection testing (CMV). I…

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -34% Danaher Corporation (DHR) -37% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -54% Lonza Group (LZAGY) -59% Agilent Technologies, Inc (A) -50%

Frequently asked questions

Is Sofiva Genomics Co (6615) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 8.94 TWD versus a price of 37.70 TWD — about −76% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6615?
Our 21-model fair value for Sofiva Genomics Co is 8.94 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 37.70 TWD.
What is the quality score of 6615?
Sofiva Genomics Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.